

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Wednesday, Nov. 10, 2021

2-6 p.m. EST

2 p.m. **Welcome: Unleashing Curiosity, Courage and Conviction for The Next Wave of Immunotherapy**
Zhen Su, MD, MBA - *Marengo Therapeutics*

Session I: Immunity Beyond T cells

Time: 2:10-3:20 p.m.
Moderator: Francesco M. Marincola, MD - *Kite, A Gilead Company*

2:10 p.m. **Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer Immunotherapy**
Dmitry I. Gabrilovich, MD, PhD - *AstraZeneca*

2:30 p.m. **Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma**
David Hou - *Northwestern University*

2:40 p.m. **A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence**
James B. Trager, PhD - *Nkarta Therapeutics*

2:50 p.m. **Panel Discussion**
Moderator: Francesco M. Marincola, MD - *Kite, A Gilead Company*
Panelists: Dmitry I. Gabrilovich, MD, PhD - *AstraZeneca*
David Hou - *Northwestern University*
Katy Rezvani, MD, PhD - *MD Anderson Cancer Center*
James B. Trager, PhD - *Nkarta Therapeutics*

Session II: CAR T and other Cell Therapies in Solid Tumors

Time: 3:20–4:30 p.m.

Moderator: Kald Abdallah, MD, PhD - *Bristol Myers Squibb*

3:20 p.m. **Equipping CAR T for Solid Tumors: Challenges and Opportunities**
Carl H. June, MD - *University of Pennsylvania*

3:40 p.m. **Secretion of Matrix Metalloproteinase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells**
Irfan N. Bandey, PhD - *University of Houston*

3:50 p.m. **AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment**
Barbra J. Sasu, PhD - *Allogene Therapeutics*

4:00 p.m. **Debate/Panel Discussion**
Moderator: Kald Abdallah, MD, PhD - *Bristol Myers Squibb*
Panelists: Irfan N. Bandey, PhD - *University of Houston*
Carl H. June, MD - *University of Pennsylvania*
Marcela V. Maus, MD, PhD - *Massachusetts General Hospital*
Barbra J. Sasu, PhD - *Allogene Therapeutics*

4:30 p.m. **Break**

Session III: Novel Combinations

Time: 4:45–6:00 p.m.

Moderator: Giovanni Melillo, MD - *AstraZeneca*

4:45 p.m. **The Evolving Landscape of Immunotherapy Combinations**
Jonathan Cheng, MD - *Bristol Myers Squibb*

5:05 p.m. **Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)**
Lawrence G. Lum, MD, DSc - *University of Virginia*

5:15 p.m. **INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma**
David A. Reardon, MD - *Dana-Farber Cancer Institute*

5:25 p.m.

Panel Discussion

Moderator: Giovanni Melillo, MD - *AstraZeneca*

Panelists: Jonathan Cheng, MD - *Bristol Myers Squibb*

Sandra Demaria, MD - *Weill Cornell Medicine*

Lawrence G. Lum, MD, DSc - *University of Virginia*

David A. Reardon, MD - *Dana-Farber Cancer Institute*

5:55 p.m.

Closing Remarks

Kald Abdallah, MD, PhD - *Bristol Myers Squibb*